Many investors turn to Benjamin Graham's so-called “Graham number” to calculate the fair price of a stock. The Graham number is √(22.5 * 5 year average earnings per share * book value per share), which for Halozyme Therapeutics gives us a fair price of $5.43. In comparison, the stock’s market price is $54.52 per share. Halozyme Therapeutics’s current market price is 904.1% above its Graham number, which implies that there is upside potential -- even for a conservative investors who require a significant margin of safety.
The Graham number is often used in isolation, but in fact it is only one part of a check list for choosing defensive stocks that he laid out in Chapter 14 of The Intelligent Investor. The analysis requires us to look at the following fundamentals of Halozyme Therapeutics:
Sales Revenue Should Be No Less Than $500 million
For Halozyme Therapeutics, average sales revenue over the last 5 years has been $644.36 Million, so in the context of the Graham analysis the stock has impressive sales revenue. Originally the threshold was $100 million, but since the book was published in the 1970s it's necessary to adjust the figure for inflation.
Current Assets Should Be at Least Twice Current Liabilities
We calculate Halozyme Therapeutics's current ratio by dividing its total current assets of $746.42 Million by its total current liabilities of $112.49 Million. Current assets refer to company assets that can be transferred into cash within one year, such as accounts receivable, inventory, and liquid financial instruments. Current liabilities, on the other hand, refer to those that will come due within one year. In Halozyme Therapeutics’s case, current assets outweigh current liabilities by a factor of 6.6.
The Company’s Long-term Debt Should Not Exceed its Net Current Assets
This means that its ratio of debt to net current assets should be 1 or less. Since Halozyme Therapeutics’s debt ratio is -1.7, the company has much more liabilities than current assets because its long term debt to net current asset ratio is -1.7. We calculate Halozyme Therapeutics’s debt to net current assets ratio by dividing its total long term of debt of $1.5 Billion by its current assets minus total liabilities of $1.65 Billion.
The Stock Should Have a Positive Level of Retained Earnings Over Several Years
Halozyme Therapeutics had good record of retained earnings with an average of $-330467949.14285713. Retained earnings are the sum of the current and previous reporting periods' net asset amounts, minus all dividend payments. It's a similar metric to free cash flow, with the difference that retained earnings are accounted for on an accrual basis.
There Should Be a Record of Uninterrupted Dividend Payments Over the Last 20 Years
We have no record of Halozyme Therapeutics offering a regular dividend within the last twenty years.
A Minimum Increase of at Least One-third in Earnings per Share (EPS) Over the Past 10 Years
There are only 9 years of EPS data available on Halozyme Therapeutics, which is short of the required 10, but it's still worthwhile to consider its EPS trend over the available period. First, we will average out its EPS for 2015 and 2016 which were $-0.25 and $-0.81 respectively. This gives us an average of $-0.53 for the period of 2015 to 2016. Next, we compare this value with the average EPS reported in 2022 and 2023, which were $1.44 and $2.10, for an average of $1.77. Now we see that Halozyme Therapeutics's EPS growth was 433.96% during this period, which satisfies Ben Graham's requirement for growth.
Based on the above analysis, we can conclude that Halozyme Therapeutics satisfies some of the criteria Benjamin Graham used for identifying for an undervalued stock because it is trading above its fair value and has:
- impressive sales revenue
- an excellent current ratio of 6.64
- much more liabilities than current assets because its long term debt to net current asset ratio is -1.7
- good record of retained earnings
- no dividend record from EDGAR
- exceptional EPS growth
